industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘drug discovery’


Monday, September 29th, 2008

RainDance Technologies signs a collaboration agreement with Sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium

LEXINGTON, MASSACHUSETTS, USA, September 29, 2008 – RainDance Technologies announced today the launch of the dScreen Consortium, a research initiative conducted with sanofi-aventis, Paris (EURONEXT: SAN and NYSE: SNY), and Louis Pasteur University of Strasbourg, France, to develop the next generation of high-throughput screening (HTS) for drug discovery applications. The consortium was founded with the assistance of the Alsace Biovalley(TM) Cluster, France, which helped secure financing and support for the program. The expected gains in terms of productivity and knowledge should accelerate the drug discovery programs.

The dScreen Consortium assembles the renowned drug screening expertise of sanofi-aventis, the unique expertise in droplet-based micro reactors of the Chemical Biology Laboratory at the Institute for Science and Supramolecular Engineering (ISIS) in Louis Pasteur University, and RainDance Technologies’ unique capabilities to apply droplet-based microfluidic technologies to human health and disease research.

“We are delighted to enter this partnership with two highly innovative research groups in this rapidly advancing field,” said Martin Galvan Ph.D., Scientific Director at the sanofi-aventis research site in Strasbourg. “The expected gains in terms of productivity and knowledge should significantly accelerate our drug discovery programs.”

Based in the Alsace Biovalley in Strasbourg, the consortium will utilize the pico-liter volumes and ultra-high speed capabilities of RainDance’s technology and systems to achieve breakthrough performance in high-throughput drug screening methodologies.

“This exciting project represents the first research collaboration undertaken by our new RainDance Technologies France SARL subsidiary,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies. “The simplicity, speed and minute volume of our technology replace current complex automation solutions in high-throughput screening. Our technology will process 10 million droplets per hour on a single benchtop instrument, dramatically accelerating the drug discovery process while conserving precious screening compounds,” added McNary.

“This project is an excellent opportunity to develop the compartmentalisation of reactions in emulsion droplets for an entirely new field of application: HTS for drug discovery,” said Andrew Griffiths, head of the Chemical Biology Laboratory at ISIS.

“The dScreen Consortium is a great illustration of the “Pôle de Compétitivité” policy in France: the development of breakthrough innovations in drug screening through collaborative R&D programs results in strengthening local actors such as the sanofi-aventis research site and in the creation of a U.S. subsidiary company in Alsace. Furthermore, the establishment of a drug screening services platform based on the results of the program will reinforce the capabilities of our cluster,” said Pascal Neuville, President of Alsace Biovalley.

More about dScreen
The aim is to develop a digital microfluidic system for quantitative HTS of bio-active compounds using purified targets and cell-based assays. The very high-throughput will enable the measurement of dose-response curves for every compound in a chemical library. The second objective is to develop a new system for compound storage in which each compound will be stored in droplets using a microfluidic device.

About the ALSACE BIOVALLEY™ cluster
The ALSACE BIOVALLEY™ cluster’s mission is to bring together and support the development and growth of all public and private players involved in the sector of life sciences and healthcare in Alsace. The ALSACE BIOVALLEY™ cluster brings together the main organizations supporting the field of life science in Alsace, thus granting all its players a simplified, more efficient and rationalized access to the entire pool of regional resources and skills.

The ALSACE BIOVALLEY™ cluster claims to be a genuine project catalyst and to hold the position of one of the main European clusters, offering entry into the unique network of excellence provided by the trinational Biovalley cluster (Alsace, Basel and Freiburg region).

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative droplet-based microfluidic solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.
For more information, please visit http://www.raindancetech.com/.

About Louis Pasteur University
Louis Pasteur University (ULP, Strasbourg, France – http://www-ulp.strasbg.fr), founding partner of EUCOR (European Federation of Universities of the Upper Rhine), is a member of the League of European Research Universities (LERU, http://www.leru.org/). A strong partnership also exists with the main French research institutions (CNRS, INSERM and INRA).

In the field of contract-based research with private companies, ULP has (since 1987) already set up a department for industrial relations and technology transfer (ULP-Industrie), which provides efficient support for the scientists.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-looking statements – sanofi-aventis
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations

bookmark to del.icio.us

Technorati tags: , , , , , , ,

Bookmark and Share

Friday, September 26th, 2008

RainDance Dedicates New Headquarters, Manufacturing Facility

LEXINGTON, MASS. – Sept. 26, 2008 — RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, today dedicated its new headquarters and operations building and unveiled its new RDT 1000 instrument.

Keynoting the event was Sir Richard Roberts, 2003 Nobel Prize winner for physiology and medicine and Founder and Chief Scientific Officer of New England Biolabs. Chris McNary, President and Chief Executive Officer, RainDance Technologies; Daniel O’Connell, Secretary of Housing and Economic Development, Commonwealth of Massachusetts; and Robert Coughlin, President and Chief Executive Officer, Massachusetts Biotechnology Council, also spoke at the event.

“The development of new technology has driven the pace of discovery in health and human disease research,” said Sir Richard Roberts. “RainDance technology has the potential to accelerate breakthroughs in genomic research and fulfill the promise of personalized medicine.”

RainDance is among the first companies to relocate to Massachusetts under Governor Deval Patrick’s innovative Life Sciences Initiative. The company cited the initiative as a major factor in moving the company’s operations from Connecticut to Massachusetts.

“Today, our dream of bringing innovative products to market is becoming a reality here in Lexington, as we dedicate this new 28-thousand square foot facility,” said Chris McNary, president and chief executive officer, RainDance Technologies. “We liked what we saw in Massachusetts. Its access to life science talent, state research grants, and the customer base of the greater Boston-Cambridge area were important requirements for our growing company,” said McNary.

RainDance cited Secretary O’Connell, the Governor’s Office, and the Massachusetts Biotechnology Council for making the company’s relocation a smooth and seamless transition.

“Strong public-private partnerships have made Massachusetts a leader in life sciences and personalized medicine with a growing base of companies and research institutions,” said O’Connell. “RainDance will play an important role in continuing that leadership.”

“We are proud to have RainDance Technologies join the impressive list of life sciences companies basing their operations in Massachusetts,” said Coughlin. “Their innovative technology and unique knowledge will add vitality to our biotechnology community.”

During the ceremony, the company unveiled a rendering of the RDT 1000 instrument, the centerpiece of its new Sequence Enrichment solution for the targeted genomic sequencing market.

“Soon, we will be delivering our sequence enrichment solution to early access partners representing some of the nation’s leading genome centers,” said McNary. “This technology will be introduced to the market during the fourth quarter, with commercial launch scheduled for the first quarter of 2009.”

RainDance’s new RainStorm™ droplet-based microfluidic technology has broad use in the prediction and prevention of human disease. The simplicity, speed, and capacity of the technology will enable numerous uses in biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection.

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative droplet-based microfluidic solutions for human health and disease research. The simplicity and speed of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

For more information, please visit www.raindancetech.com.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , , , , ,

Bookmark and Share

Monday, September 22nd, 2008

RainDance Technologies to Dedicate New Biomedical Technology Facility in Lexington

MEDIA ALERT — UPCOMING NEWS EVENT
RainDance Technologies to Dedicate New Biomedical Technology Facility in Lexington

– Biomedical technology innovator relocates to Mass. based upon Gov. Deval Patrick’s Life Sciences Initiative –

  • WHEN: Friday, Sept. 26, 2008, 3:00 p.m. to 5:00 p.m. EDT
  • WHERE: 44 Hartwell Avenue, Lexington, Mass.

RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, will dedicate its new headquarters and commercial and manufacturing operations on Friday, Sept. 26th in Lexington, Mass. at 3:00 p.m.

RainDance’s 28,000-square-foot building in Lexington will more than double its former space in Guilford, Conn. RainDance plans to increase its workforce by some 50 percent – adding new biologists and chemists, mechanical engineers and technicians, software programmers, customer service representatives, and administrative support – and will employ nearly 100 within the year.

Company officials made the decision to relocate to Massachusetts based on Governor Deval Patrick’s Life Sciences Initiative.

RainDance will also announce a collaboration with a major pharmaceutical company to develop a new droplet-based methodology for the drug discovery process.

AgendaRemarks:

  • Sir Richard Roberts, Nobel Laureate, Physiology/ Medicine, 1993, RainDance Technologies Scientific Advisory Board
  • Daniel O’Connell, Massachusetts Housing and Economic Development Secretary
  • Christopher McNary, RainDance Technologies President and Chief Executive Officer
  • Robert Coughlin, president of the Massachusetts Biotechnology Council

A tour of our new facilities and reception will follow.

RainDance’s new RainStorm™ droplet-based microfluidic technology has broad use in the prediction and prevention of human disease. The simplicity, speed, and capabilities of the technology will enable researchers to design experiments in ways previously unaffordable or unimaginable. RainStorm technology will find numerous uses in biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection.

RainDance was founded by scientists from Harvard University, the Medical Research Centre in Cambridge, England, and the ESPCI in Paris, and the company’s scientific advisers include three Nobel Prize winners plus a pioneer in protein engineering who has been knighted for services to molecular biology.

For further information: Don Goncalves, dgoncalves@tizinc.com, 781-793-9380; Cortney Lusignan, clusignan@tizinc.com, 781-793-9380.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , , , , , , ,

Bookmark and Share

Wednesday, August 13th, 2008

RainDance Technologies Appoints Olex Vice President, System Development

LEXINGTON, Mass., Aug 13, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Michael B. Olex as Vice President, System Development, effective immediately.

“As RainDance introduces its exciting RainStorm(TM) droplet-based technology to market, Mr. Olex will play a key leadership role in designing, developing, and integrating complete systems for commercialization, including instrumentation, consumables, and reagents,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “He will immediately focus on our Sequence Enrichment application for targeted genomic sequencing that will be launched later this year. With his deep experience in life sciences management, Mr. Olex will establish productive, efficient product transfer procedures from engineering to manufacturing, including the development of manufacturing processes,” McNary said.

Olex joins RainDance from BioTrove, where he was Vice President, Manufacturing, and established the company’s OpenArray(TM) consumable and instrumentation manufacturing departments. He also served as Senior Vice President at U.S. Genomics; President of International Light; Director, Business Projects at Applied Biosystems; and Vice President of Manufacturing at PerSeptive Biosystems. Olex holds a master of business administration degree from Case Western Reserve University, a master of science degree in electrical engineering from Cleveland State University, and a bachelor’s degree in electrical engineering from the University of Detroit.

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative droplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

For more information, please visit http://www.raindancetechnologies.com/. For more information, please visit http://www.raindancetechnologies.com/.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Bookmark and Share

Wednesday, July 9th, 2008

RainDance Technologies Announces Formation of French Subsidiary

LEXINGTON, MASSACHUSETTS, USA July 9, 2008 — RainDance Technologies, Inc., a provider of innovative droplet-based solutions for human health and disease research, today announced the formation of RainDance Technologies France SARL, a wholly owned subsidiary focused on securing research partnerships in Europe. Based in Strasbourg, RainDance Technologies France SARL will begin operations by September 1, 2008.

“The creation of RainDance Technologies France SARL enhances our company’s ability to collaborate with leading European institutions engaged in drug discovery, genomics, and molecular biology research,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “In addition, it will position our proven droplet-based technology for new business opportunities as we expand our presence in the growing European market. RainDance Technologies’ speed and simplicity will enable biomedical researchers to design experiments in ways that were previously unaffordable or unthinkable.”

To house its new subsidiary, RainDance has leased facilities at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS), Université Louis Pasteur, in Strasbourg.

“Locating our offices at ISIS will continue our close relationship with Dr. Andrew Griffiths, a RainDance founder and the Director of the ISIS Chemical Biology Laboratory,” said McNary. “Dr. Griffiths is renowned for his work in the development of phage display for the selection of human antibodies for therapy, and for the development of a novel technique for selection and directed evolution of both nucleic acids and proteins. His support and guidance will be significant assets as we identify and engage in new research partnerships,” he said.

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative droplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

For more information, please visit http://www.raindancetechnologies.com/.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Bookmark and Share

Monday, June 2nd, 2008

RainDance Appoints Kelly Chief Operating Officer

LEXINGTON, MASSACHUSETTS, June 2, 2008RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Roch W. Kelly as Chief Operating Officer, effective immediately.“As RainDance solutions enter commercial development, Mr. Kelly is the ideal leader to establish our manufacturing and financial capabilities,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “With more than 20 years of experience in life sciences, he brings a proven record of successfully implementing the process and controls in these critical areas to meet the anticipated demand for our products.”

Kelly joins RainDance from Synarc, Inc., where he was Vice President, Clinical Operations. Under his leadership, the operational team rapidly implemented new processes and systems that achieved a 25% improvement in efficiency. Previous positions included Chief Operating Officer and Chief Financial Officer at Protedyne, Inc., and Vice President, Clinical Operations and Worldwide Business, at PAREXEL International. He also served as Executive Director of Manufacturing Operations at Chiron Diagnostics. Kelly received a bachelor of science degree in finance from Miami (Ohio) University and a master’s of business administration degree from Syracuse University.

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-sized droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

For more information, please visit http://www.raindancetechnologies.com/.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , ,

Bookmark and Share

Monday, May 19th, 2008

RainDance Announces Company Relocation and Manufacturing Start-Up

GUILFORD, CONNECTICUT, May 19, 2008RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the relocation of the company from Guilford, Connecticut, to Lexington, Massachusetts. RainDance said it will open the new facility and start up commercial and manufacturing operations effective May 27, 2008.

“With the launch of our first life sciences application scheduled for the fourth quarter of this year, it’s important for RainDance to be located in the nation’s preeminent biotechnology center,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “As we enter the commercial phase of product development and begin manufacturing operations, a larger facility and access to the exceptional life sciences talent pool and customer base of the greater Boston/Cambridge area will be essential.”

The company said it will employ approximately 65 people at the Lexington facility by the end of the year. “During the coming months, we will be hiring about 30 people, including biologists and chemists, mechanical engineers and technicians, software programmers, customer service representatives, and administrative support,” said McNary.

RainDance’s new 28,000-square-foot building in Lexington, located at 44 Hartwell Avenue, more than doubles the space of its present Guilford, Connecticut, facility. The building will house the firm’s executive and administrative offices, research and development group, sales and marketing team, and manufacturing operations. In addition, the company plans to purchase more than $500,000 in scientific and office equipment.

“This move locates RainDance in a community of scientific investigators and laboratories that is closely aligned with our business and technology,” McNary said.

Effective May 27, 2008, RainDance Technologies’ new contact information will be as follows:
44 Hartwell Avenue
Lexington, MA 02421-3103
Phone — 781-861-6300
Fax — 781-861-1233

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-sized droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. The droplets are processed on a small chip that has no moving parts or valves. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter.

For more information, please visit www.raindancetechnologies.com.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , ,

Bookmark and Share

Tuesday, March 18th, 2008

RainDance Appoints Becker Chief Commercial Officer

GUILFORD, CONNECTICUT, March 18, 2008RainDance Technologies, Inc., a developer of NanoReactor droplet-based microfluidic technology, today announced the appointment of Stephen E. Becker as Vice President, Commercial Officer, effective immediately.

“Mr. Becker will be responsible for continuing the growth of the company’s commercial operations as it prepares for the launch of its first life science offering,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “These duties will include the continued development of the sales channels, leading customer service and support programs, and development of the strategic marketing plan.”

The RainDance platform combines emulsion-based droplets and microfluidics to enable a host of existing applications in the company’s nano-scale format, including genomic analysis, cell-based assays, and single molecule detection. Samples such as cells, nucleic acids, proteins, beads, and chemical compounds are encapsulated in individual micron-sized droplets on assay-specific microfludic chips. Since each droplet is the equivalent of a well in a microtiter plate, the RainDance platform can process and analyze up to 10,000 samples per second with unparalleled accuracy.

Becker joins RainDance from Agilent Technologies, where he served as Senior Sales Manager in the company’s Americas Field Operations. There, he led the commercial introduction of novel genetic and epigenetic microarray assays that achieved over 20% growth rates in 2006 and 2007 in the research and molecular diagnostics markets. At GE Healthcare (formerly Amersham Pharmacia Biotech), Becker held several senior management assignments, including Director, Gene and Protein Discovery, and Director, Business Support. He also held sales management positions at Spectrum Chemical Manufacturing Corporation and Curtin Matheson Scientific, Inc. Becker received a bachelor’s degree in biology from St. Mary’s College of California.

“The RainDance droplet technology is a new tool that will allow scientists to accelerate their research through the advantages provided by nano-scale reactions at unparalleled assay speeds in the life science, diagnostic, and industrial markets,” said McNary. “Mr. Becker’s broad experiences will help us develop best-in-class commercial processes that support the introduction of our exciting technology.”

About RainDance Technologies, Inc.
RainDance Technologies, Inc., is a biomedical technology company devoted to developing and commercializing a proprietary droplet-based microfluidics platform. The core of our technology is the generation of stable, nano-liter sized droplets that act as the functional equivalent of a test tube, or a well on a microtiter plate. Each droplet can encapsulate an individual sample of cells or reagents for both preparative and analytical life science and chemical analysis applications. RainDance recognizes that the rate and scale of research are accelerating dynamically, and for researchers to keep pace with these demands, they need the benefits of high-quality individualized reactions generated on a massive scale. Our vision is to be the worldwide leader in massively parallel sample processing and analytical solutions that provide a new standard of data quality.

RainDance has developed instrumentation and disposable microfluidic circuits that enable researchers to generate experimental results faster than existing methodologies, with increased throughput and decreased experimental variability. We will provide these tools to academic and commercial researchers working on a variety of basic and applied research applications. Our proprietary emulsion chemistries and microfluidic manufacturing process allow our platform to miniaturize many biological and chemical assays. These same core attributes will allow the RainDance platform to perform biological and chemical applications previously unimaginable or unaffordable using conventional laboratory or microfluidic techniques.

The company was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter.

The company’s areas of focus include genomics, proteomics, cell biology, and molecular diagnostics. Importantly, we continue to expand our capabilities by partnering with the research community and commercial development partners to generate novel applications of the core RainDance technology.

For more information, please visit http://www.raindancetechnologies.com/.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , ,

Bookmark and Share

Thursday, November 29th, 2007

RainDance Technologies Selected As A World Economic Forum Technology Pioneer

Guildford, Connecticut, USA — 29 November 2007 – RainDance Technologies has been selected as a World Economic Forum Technology Pioneer. Technology Pioneers were nominated by the world’s leading technology experts and final selection from 273 nominees was made by a panel of leading technology experts. Technology Pioneers are invited to participate in the World Economic Forum Annual Meeting in Davos, Switzerland

Dr. Jonathan M. Rothberg, co-founder and chairman of RainDance Technologies was selected to represent RainDance as a 2008 Technology Pioneer at Davos this year.

“We started RainDance with an amazing group of co-founders and advisors with the mission to have a profound impact on the way life science research is undertaken, we wanted to create the laboratory equivalent of the personal computer”, said Dr. Rothberg. “Our vision ‘A RainDance Professional Laboratory System in every lab’ has attracted an active scientific advisory board including three Nobel Prize winners. It is great to have RainDance recognized by the World Economic Forum as a company with the potential to change people’s lives – to improve the way people do research from fields as diverse as the life sciences and bio-energy.”

While RainDance has affected the way it’s academic and industrial partners do research, RainDance is now focused on delivering its products to the world’s market in 2008. RainDance designed the Professional Laboratory System (PLS) to be the biochemical equivalent of a personal computer. The key to this innovation is the novel combination of microdroplets and microfluidics to create and route digital packets of biochemical information called NanoReactors. The PLS is a versatile lab-on-chip, able to perform laboratory functions at speeds and complexities not possible with existing instruments. Like a computer manipulates bits of information, the PLS enables the programmable handling of fluid samples for innovative assay and screening applications.

Technology Pioneers are companies that have been identified as developing and applying highly transformational and innovative technologies in the areas of energy, biotechnology and health, and information technology. To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership, show all the signs of being a long-standing market leader – and its technology must be proven. Previous Technology Pioneers have included Business Objects, Cambridge Silicon Radio, Corel Corporation, Encore Software, Google, Mozilla Corporation and Napster.

Twenty-three of the Technology Pioneers 2008 are US-based companies. Israel and the United Kingdom each boast three; Sweden and Switzerland two each; Canada, France, Germany, India, the Netherlands and Russia, one each. Technology Pioneers are nominated in three main categories: Energy/Environment, Biotechnology/Health and Information Technology.

“This year the World Economic Forum received a record number of applications from companies around the world to become a Technology Pioneer. From a highly competitive field, we are extremely pleased to have a community that is using innovation and technology to dramatically affect the way society and business operate and doing so in a markedly collaborative manner. We are excited to welcome the Technology Pioneers class of 2008 to the larger community of the World Economic Forum and we are looking forward to the fruits that their collaboration will bring,” said Peter Torreele, Managing Director of the World Economic Forum.

About Dr. Jonathan Rothberg
Dr. Rothberg was born in 1963 in New Haven, Connecticut. He earned a B.S. in chemical engineering from Carnegie Mellon University and a Ph.D. in biology from Yale University. Most recently Dr. Rothberg completed the first sequence of an individual human being (James D. Watson) and initiated the Neanderthal Genome project. Dr. Rothberg is the founder of 454 Life Science, Clarifi Corporation, CuraGen Corporation, , Ion Torrent Systems, The Rothberg Institute for Childhood Diseases, and the co-founder and Chairman of RainDance Technologies. Dr. Rothberg was named an Ernst and Young Entrepreneur of the Year and is the receipt of The Wall Street Journal’s Gold Medal for Innovation for his invention of 454 sequencing, and The Irvington Institute’s Corporate Leadership Award in Science. His scientific work has been featured on the covers of Cell, Science, and Nature. Dr. Rothberg’s invention of the first new way to sequence DNA on a chip – 454 Sequencing, has been instrumental in work as diverse as solving the mystery behind the disappearance of the honey bee and unlocking the complexity of the world’s ecosystems. Dr. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, and serves on the board of trustees of Carnegie Mellon University.

About Raindance Technologies
RainDance Technologies, Inc. is a nanotechnology company devoted to developing and commercializing the Professional Laboratory System, a platform for droplet-based microfluidics. The Professional Laboratory System is an integrated fluid handling system that provides precise manipulation of minute amounts of fluids for a variety of industrial and research applications within genomic, drug discovery, industrial enzyme development, and molecular diagnostic markets. At the core of the system’s power are assay-specific NanoReactor chips composed of fluid handling modules that encapsulate samples and reactants in individual micron-sized droplets. Founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris, RainDance Technologies designed the Professional Laboratory System to enable a host of nanoscale assays including cell-based and single molecule experiments. Samples (cells, beads, DNA templates, chemical compounds) and reactants are encapsulated in individual micron-sized droplets on assay-specific NanoReactor chips. With each droplet being the equivalent of a well in a microtiter plate, the Professional Laboratory System can process and analyze up to 10,000 samples per second with unparalleled accuracy. The precise manipulation of minute amounts of fluids within NanoReactor droplets will benefit a variety of industrial and research applications, including DNA sequencing preparation, enzyme engineering, functional cell sorting, multiplex PCR, SNP detection, gene expression, and RNAi functional assays. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter. For more information, please visit http://www.raindancetechnologies.com/.

About the World Economic Forum
The World Economic Forum is an independent international organization committed to improving the state of the world by engaging leaders in partnerships to shape global, regional and industry agendas.

Incorporated as a foundation in 1971, and based in Geneva, Switzerland, the World Economic Forum is impartial and not-for-profit; it is tied to no political, partisan or national interests. (http://www.weforum.org).

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com

bookmark to del.icio.us

Technorati tags: , , , , , , , ,

Bookmark and Share

Wednesday, November 28th, 2007

RainDance Technologies Appoints McNary President and CEO

Guilford, Connecticut, USA, November 28, 2007 – RainDance Technologies, Inc., a developer of NanoReactor droplet-based microfluidic technology, today announced the appointment of Christopher McNary as President and Chief Executive Officer. McNary will join Jonathan Rothberg, Chairman of the Board, in driving RainDance Technologies’ vision and the upcoming commercial launch of its Professional Laboratory System in the Life Sciences and other related markets.

“Mr. McNary joins an outstanding leadership team that includes a distinguished Scientific Advisory Board with three Nobel Prize recipients and a Board of Directors with the former Presidents of Applied Biosystems and Affymetrix, plus an experienced Partner from Mohr Davidow Ventures,” said Rothberg. “He will assist us in attracting additional talent to develop first-rate manufacturing and customer support capabilities and to commercially launch our exciting new products and applications.”The RainDance Professional Laboratory System combines microdroplets and microfluidics to enable a host of nanoscale cell-based and molecular assays. Samples (cells, beads, DNA templates, chemical compounds) and reactants are encapsulated in individual micron-sized droplets on assay-specific NanoReactor chips. With each droplet being the equivalent of a well in a microtiter plate, the Professional Laboratory System can process and analyze 10,000 samples per second with unparalleled accuracy. The precise manipulation of minute amounts of fluids within NanoReactor droplets will benefit a variety of industrial and research applications, including DNA sequencing preparation, enzyme engineering, functional cell sorting, multiplex PCR, SNP detection, gene expression, and RNAi functional assays.

“Our Professional Laboratory System is game-changing technology that has attracted a tremendous level of market interest,” said Darren Link, Senior Vice President of Research and Development and RainDance Technologies founder. “Mr. McNary’s depth of expertise and proven leadership in the commercialization of life science tools will be instrumental in guiding our company’s growth. I look forward to working with him and our visionary Board of Directors to transform the future of laboratory practices,” he said.

Mr. McNary has more than 25 years of experience in Life Sciences and Diagnostic markets with 14 years in senior management positions. He joins RainDance from Thermo Fisher Scientific where he was Vice President and General Manager. He also has served as President and CEO of early-stage start-up companies and held executive management positions at Chiron Diagnostics and Tecan.

“RainDance has built an impressive management team supported by a Scientific Advisory and Board of Directors with the proven experience in commercializing innovative technology platforms such as the Professional Laboratory System,” said McNary. “This team and platform are well positioned to realize the full benefits of microfluidics in a variety of markets and applications.”

About RainDance Technologies, Inc.
RainDance Technologies, Inc. is a nanotechnology company devoted to developing and commercializing the Professional Laboratory System, a platform for droplet-based microfluidics. The Professional Laboratory System is an integrated fluid handling system that provides precise manipulation of minute amounts of fluids for a variety of industrial and research applications within genomic, drug discovery, industrial enzyme development, and molecular diagnostic markets. At the core of the system’s power are assay-specific NanoReactor chips composed of fluid handling modules that encapsulate samples and reactants in individual micron-sized droplets. Founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris, RainDance Technologies designed the Professional Laboratory System to be the chemical equivalent of a personal computer. As a computer manipulates bits of information, the system’s NanoReactor technology enables the programmable handling of cells and fluid samples for innovative assay and screening applications. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter. For more information, please visit http://www.raindancetechnologies.com/.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , ,

Bookmark and Share

Industry PR is proudly powered by WordPress.
WordPress